Ownership and insider activity for Alector, Inc. (ALEC): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders.
Price
| Price | $1.93 |
| Market Cap | $214M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-02 | Wong-Sarad Grace | S-Sale | 656 | $2K |
| 2026-09-03 | Wong-Sarad Grace | S-Sale | 5,165 | $14K |
| 2026-09-04 | Wong-Sarad Grace | S-Sale | 3,625 | $9K |
| 2026-09-03 | Berkley Neil Lindsay | S-Sale | 29,251 | $78K |
| 2026-09-03 | Rosenthal Arnon | S-Sale | 72,606 | $193K |
| 2026-08-19 | Rosenthal Arnon | G-Gift | 350,000 | |
| 2026-08-19 | Rosenthal Arnon | G-Gift | 1,050,000 | |
| 2026-07-09 | Wong-Sarad Grace | A-Award | 20,000 | |
| 2026-06-17 | Yaffe Kristine | A-Award | 28,700 | |
| 2026-06-17 | Yaffe Kristine | A-Award | 9,450 |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $50.8M | $32.5M | $65.5M | $89.6M | $50.0M | $329.2M | $154.3M | $74.6M | $33.0M | $65.8M |
| Short-term Investments | 0 | 0 | $224.9M | $263.4M | $363.3M | $406.1M | $558.5M | $474.3M | $380.4M | $190.2M |
| Receivables | $218000 | $200.2M | 0 | 0 | 0 | $7.4M | $2.6M | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $51.2M | $233.0M | $293.2M | $357.4M | $421.5M | $749.7M | $726.4M | $565.8M | $424.8M | $266.5M |
| Property, Plant & Equipment | $2.5M | $2.8M | $10.9M | $62.3M | $62.7M | $57.9M | $53.3M | $47.1M | $37.1M | $24.6M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $54.1M | $236.1M | $308.4M | $421.9M | $488.3M | $814.7M | $787.6M | $621.8M | $468.3M | $293.2M |
| Accounts Payable | $1.2M | $1.1M | $126000 | $278000 | $3.0M | $4.7M | $4.2M | $3.8M | $2.2M | $1.7M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $366000 |
| Total Current Liabilities | $1.5M | $27.4M | $13.0M | $62.0M | $68.1M | $139.6M | $93.8M | $177.9M | $125.1M | $69.5M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $9.4M | $9.3M |
| Total Liabilities | $79.0M | $288.1M | $405.8M | $227.2M | $220.7M | $513.9M | $573.2M | $487.7M | $341.5M | $262.6M |
| Retained Earnings | -$29.7M | -$62.2M | -$114.4M | -$219.8M | -$410.0M | -$446.4M | -$579.7M | -$710.1M | -$829.1M | -$972.1M |
| Total Equity | -$24.9M | -$52.0M | -$97.4M | $194.7M | $267.5M | $300.7M | $214.4M | $134.2M | $126.8M | $30.6M |
| Total Debt | 0 | 0 | 0 | $48.0M | $51.3M | $47.6M | $43.3M | $38.9M | $42.5M | $36.2M |
| Net Debt | -$50.8M | -$32.5M | -$290.4M | -$305.0M | -$362.1M | -$687.6M | -$669.5M | -$509.9M | -$370.9M | -$219.8M |
| Working Capital | $49.7M | $205.6M | $280.1M | $295.5M | $353.4M | $610.2M | $632.6M | $387.9M | $299.8M | $196.9M |
Financial Health
| Debt / Equity | -3.29 |
| Current Ratio | 5.26 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -5.04 |
Profitability
| Return on Equity | -531.04% |
| Return on Invested Capital | -67.56% |
| Return on Assets | -58.10% |
| Gross Margin | -360.92% |
| Operating Margin | -914.56% |
| Net Margin | -850.13% |
Related companies: ABOS · APLT · CRBP · FATE · IRD · MOLN · NKTX
Explore sector: Healthcare · Biotechnology
More sections of ALEC: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks